🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

GLOBAL MARKETS-Vaccine progress lifts stocks, dollar still sickly

Published 11/23/2020, 09:13 PM
Updated 11/23/2020, 09:20 PM
© Reuters.
EUR/USD
-
USD/ZAR
-
USD/MXN
-
XAU/USD
-
USD/RUB
-
DX
-
GC
-
LCO
-
CL
-
NQZ24
-
DE10YT=RR
-
STOXX
-
MIAPJ0000PUS
-
MRNA
-
BNTX
-

* AstraZeneca vaccine news drives risk-on approach
* Australia eases lockdowns, U.S. vaccines in sight
* Stocks hit record highs https://tmsnrt.rs/3nUxlfj
* EM FX no longer split by U.S. election https://tmsnrt.rs/3lVcw2w

By Lawrence White and Andrew Galbraith
LONDON/SHANGHAI, Nov 23 (Reuters) - Investors scooped up
stocks, commodities and emerging-market currencies and gave the
dollar a wide berth as AstraZeneca and Oxford University
provided markets with their now-regular Monday shot of
encouraging COVID-19 vaccine news.
The STOXX index of Europe's 600 largest firms .STOXX rose
to its highest since February, Wall Street was pointing up 0.6%
.N and Brent futures were nearly 1.5% stronger LCOc1 .
AstraZeneca and Oxford vaccine, which is set to cost just a
few dollars a shot and should be easier to ramp up and store
than vaccines by Pfizer PFE.N and BioNTech 22UAy.F BNTX.O
and Moderna MRNA.O , could also be up to 90% effective.
As the dollar buckled through a range it has been in for the
past few months, the euro touched $1.19 EUR= , but it was the
emerging markets that are likely to benefit from a cheaper and
easier-to-store drug that rallied the most. /FRX
South Africa's rand ZAR= shrugged off a double sovereign
credit-rating downgrade over the weekend to add 0.8%. Russia's
rouble RUB= and Mexican peso MXN= both climbed half a
percent to bolster their stellar months. EMRG/FRX
"The combined vaccine news of the last few weeks... will
lead to a much faster pace of normalization to our daily lives
compared to what we would have assumed just a few weeks ago,"
analysts at Deutsche Bank said in a note to clients. "By spring,
things should be looking much closer to normal."
Markets' optimism also came after a top official of the U.S.
government's vaccine-development effort said Sunday that the
first vaccines there could be given to U.S. healthcare workers
and some others by mid-December. U.S shares looked set to mimic gains in Europe and Asia, as
Nasdaq futures NQc1 rose 0.4%, Dow futures rose 0.7%, and U.S.
e-mini futures for the S&P 500 EScv1 were 0.6% higher at
3,576.
The rally also showed investors are willing to look past the
grim U.S. case numbers -- which topped 12 million over the
weekend -- and mixed European economic data released on
Monday.
IHS Markit's headline flash composite PMI, seen as a good
guide to economic health, fell to 45.1 in November from
October's 50.0 - the level separating growth from contraction. A
Reuters poll had predicted a shallower dip to 46.1.
Vaccine hopes, though, and expectations of more stimulus
from the European Central Bank next month, meant optimism
improved. The composite future output index jumped to 60.1 from
56.5, its highest since February.
"Today's vaccine news is positive, but it is only partly
responsible for the rally in stock markets," said Philip Shaw,
chief economist at Investec in London. "(It) is also being
driven by the news that the U.S. hopes to start the vaccination
program in under three weeks."

GOLD LOSING ITS SHINE
Euro zone government bonds saw some selling as investors
also focused on the fact that major economies remain under
strict lockdowns and that COVID-19 cases are not receding.
Benchmark German 10-year Bund yields were last flat at
-0.57% DE10YT=RR , off a two-week low.
The European share rally took the region's November gains to
15% and followed another record high for Asian equities even
before the announcement of latest vaccine news.
MSCI's broadest index of Asia-Pacific shares outside Japan
.MIAPJ0000PUS ended the day 0.8% higher.
Analysts said the gains belied some uncertainty as monetary
and fiscal help for the U.S. economy remained elusive.
U.S. Treasury Secretary Steven Mnuchin said last week that
key pandemic lending programs at the Federal Reserve would
expire on Dec. 31, putting the outgoing Trump administration at
odds with the central bank and potentially adding stress to the
economy. With the vaccine news and dollar index =USD , which tracks
the dollar against a basket of six major rivals, down to 92.097,
commodity markets were still bullish, with traders optimistic
about a recovery in crude demand pushing oil higher.
West Texas Intermediate crude CLc1 gained 71 cents, or
1.67%, to $43.13 a barrel, in line with the gains in Brent crude
futures. Both benchmarks jumped 5% last week.
Safe-haven gold XAU= , meanwhile, drifted at $1,864 per
ounce, having lost almost 10% since peaking in earlier August.
GOL/
"Positive sentiment continues to be driven by the recent
good news about the efficacy of coronavirus vaccines in
development and the expectation that the OPEC+ meeting at the
end of this month could see the group extend current cuts by
three to six months," said Stephen Innes, chief global markets
Strategist at Axi, a financial services firm.



<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
World FX rates in 2020 http://tmsnrt.rs/2egbfVh
2020 asset performance http://tmsnrt.rs/2yaDPgn
Vaccine hopes send world stocks to record highs https://tmsnrt.rs/3nUxlfj
EM FX was split by U.S. election...not any longer https://tmsnrt.rs/3lVcw2w
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.